Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- H. pylori Eradication Could Greatly Reduce Medical Expenditure; Manufacturers of PPIs Will Need to Educate the Public
May 31, 2013
- Outline of Growth Strategy Embraces Japan-Version NIH, Promotion of Special System for Mixed Healthcare
May 30, 2013
- 45 Face-to-Face Consultation Meetings Provided through PMDA’s Regulatory Strategy Consultation Service as of March 2013
May 30, 2013
- MHLW Reprimands Novartis over Diovan Papers
May 29, 2013
- Report of MOF’s Fiscal System Council Calls for 100% Generic Share Target
May 29, 2013
- PAFSC’s Second Committee Recommends Approval for IV Preparation of Acetaminophen
May 28, 2013
- First Committee Recommends Approval for Third GLP-1 Receptor Agonist Lyxumia, Others
May 27, 2013
- “Strong Guidance Will Be Required” in Diovan Case: Health Minister Tamura
May 27, 2013
- Citations in Guidelines to Be Prerequisite for Health Coverage of Off-Label Drugs under 1980 Notification
May 24, 2013
- New Rules to Promote Generic Drug Use by Welfare Recipients to Take Effect This Year
May 23, 2013
- MOF Official Expresses Caution on Perpetuation of New Drug Premium, Citing “Need for Continual Verification”
May 22, 2013
- MHLW Orders Marketing Authorization Holders of Careram/Kolbet to Issue a “Blue Letter”
May 21, 2013
- PM Abe Indicates that Next Fiscal Reform Plan Will Not Include Controls on Growth Rate of Social Security Spending
May 20, 2013
- NIBIO Establishes Center for Innovative Drug Discovery and Development, Appoints Yoichi Kurebayashi as Director
May 20, 2013
- 39 Companies Report Discontinuing Supplies of Generics within 5 Years: MHLW Survey
May 17, 2013
- Government Aims for 60% Generic Drug Share by End of FY2017; Some See Shortcomings in Roadmap
May 17, 2013
- Pharma Execs Call for Perpetuation of Premium at 1st Public-Private Dialogue under PM Abe’s Second Cabinet
May 16, 2013
- CSIMC Approves Listing of 15 New APIs/19 Products Including Pfizer’s Xeljanz with Expected Peak Sales of 59.7 Billion Yen
May 16, 2013
- 1st Committee on New Drugs to Discuss GLP-1 Agonist Lyxumia, Other New Drugs on May 24
May 15, 2013
- PMDA-WEST to Be Launched in Osaka in October to Undertake Consultation Services, GMP Inspections
May 13, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…